Liposomal daunorubicin
From Wikipedia, the free encyclopedia
 |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (April 2008) |
Liposomal daunorubicin is a chemotherapy drug that is FDA approved to treat AIDS-related Kaposi's sarcoma. It is also commonly used to treat specific types of leukaemia and non-Hodgkin lymphoma. Liposomal daunorubicin is intravenously administered. It utilizes the liposomal carrier system that provides a favorable pharmacokinetic profile at the site of KS lesions resulting in a 10-fold increase in concentrations compared to that which is achieved with conventional preparations.
Trade name: DaunoXome
[edit] External links
- Cancerbackup Liposomal daunorubicin (DaunoXome)
- Women&Cancer Magazine Liposomal daunorubicin
- Johns Hopkins AIDS Service - New from the Food and Drug Administration (FDA)
 |
This oncology article is a stub. You can help Wikipedia by expanding it. |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
